Inhibitory monoclonal antibody against blood clotting factor VII-activating protease

US7829095B2 · kind B2 · utility

Assignee

• CSL Behring AG · DE

Inventors

• Juergen Roemisch · Marburg, DE
• Wiegand Lang · Cölbe, DE
• Annette Feussner · Marburg, DE
• Gudrun Muth-Naumann · Wetter, DE
• Hans-Arnold Stoehr · Wetter, DE
• Christian Kannemaier · Gießen, DE
• Klaus Preissner · Gießen, DE
• Fumie Nakazawa · Tokyo, JP

Key dates

• Filing date: Feb 7, 2003
• Grant date: Nov 9, 2010
• Expiry date: Feb 7, 2023

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2333/96447
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A monoclonal antibody which inhibits the blood clotting factor VII-activating protease and its proenzyme and a blood clotting factor VII-activating protease, stabilized by the addition of said monoclonal antibody, and its proenzyme are described. A suitable monoclonal antibody is produced by hybridoma cell line DSM ACC 2533. The application of the inhibitory, monoclonal antibody in the stabilization of blood clotting preparations and in preparations for reducing the coagulability of the blood is disclosed.